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Alzheimer’s disease (AD) is the most common form of dementia, and the pathological changes of senile plaques (SPs) and
neuroﬁbrillary tangles (NFTs) in AD brains are well described. Clinically, a diagnosis remains a postmortem one, hampering both
accurate and early diagnosis as well as research into potential new treatments. Visual deﬁcits have long been noted in AD patients,
and it is becoming increasingly apparent that histopathological changes already noted in the brain also occur in an extension of the
brain; the retina. Due to the optically transparent nature of the eye, it is possible to image the retina at a cellular level noninvasively
and thus potentially allow an earlier diagnosis as well as a way of monitoring progression and treatment eﬀects. Transgenic animal
models expressing amyloid precursor protein (APP) presenilin (PS) and tau mutations have been used successfully to recapitulate
the pathological ﬁndings of AD in the brain. This paper will cover the ocular abnormalities that have been detected in these
transgenic AD animal models.
1.Introduction
Alzheimer’s disease (AD) is a form of dementia aﬀecting 26.6
million people worldwide as of 2006; a ﬁgure predicted to
quadrupleby2050[1].Itmanifestsclinicallywithprogressive
cognitive impairment that can be divided into a predementia
phaseandmild,moderate,andseveredementiaphaseswhich
areincreasinglyaccompaniedbynoncognitiveandneurolog-
ical disturbances [2].
Therehasbeenmuchworkinvestigatingthepathogenesis
ofADwhichhasresultedinseveralkeyﬁndingsallowingfor-
mation of several hypotheses.
The most well-regarded theories as to the pathology un-
derlying the degeneration of neurons in the brain are the for-
mation of extracellular senile plaques (SPs) via amyloid-beta
(Aβ) deposition [3] and formation of intracellular neuroﬁ-
brillary tangles (NFTs) via hyperphosphorylation of tau pro-
tein [4]. Indeed the presence of SPs and NFTs remain the
mandatorypathologicalﬁndingstomakeadeﬁnitivediagno-
sis[5],astipulationthathasnotchangedsincetheywereﬁrst
described in 1906 by Alois Alzheimer [6].
The exact mechanisms as to how Aβ deposition and NFT
formation cause neurotoxicity and neuronal loss remain
unclear although several factors have been postulated. These
include increased oxidative stress by production of reactive
oxygen species by Aβ [7, 8], increased oxidative stress
mediated by metal ions within Aβ [9], and interaction of Aβ
peptides with the N-methyl-d-aspartate (NMDA) receptor
resulting in neurotoxicity [10]. Additional theories of AD
pathogenesisincludechronicinﬂammation[11]andreduced
synthesis of acetylcholine [12]. The diﬀerent hypotheses
proposed are summarised in Table 1.
In fact, to go back a step in the pathogenesis of AD, it is
also not clear what causes the aggregation of Aβ as amyloid
plaques; however, there is much evidence that it involves the
dyshomeostasis of metal ions. Aβ is known to precipitate out
in the presence of primarily zinc but also copper and iron
ions [20]d u et oah i g h - a ﬃnity metal-binding site [21], and
occupationofthisbindingsitehasbeenshowntopreventthe
formation of Aβ from APP by inhibiting the initial cleavage
of APP by α-secretase [22]. The relevance to AD is clear in
that pathology only seems to occur when Aβ precipitates out2 International Journal of Alzheimer’s Disease
Table 1: Hypotheses implicated in the development of Alzheimer’s disease.
Mechanisms implicated in AD Pathophysiology References
Amyloid hypothesis Aggregation of Aβ peptides produces oligomers resulting in
neurotoxicity and neuronal loss [13–16]
Tau hypothesis
Hyperphosphorylation of tau proteins causes misfolding of
microtubules, which leads to formation of NFT and disruption of the
neuronal cytoskeleton
[17, 18]
Cholinergic hypothesis Loss of cholinergic neurotransmission in the cerebral cortex. Oldest
hypothesis on which current available treatments are based on [12]
Glutamatergic hypothesis
This hypothesis links AD to neuronal damage caused by
overactivation of N-methyl-d-aspartate (NMDA) receptors by
glutamate. It is suggested that low activation of NMDA receptor is
essential for learning and memory
[10]
Oxidative Stress hypothesis
In AD brains, Aβ generates reactive oxygen and nitrogen species
which react with other molecules to form free radicals causing
molecular and cellular damage Oxidative damage is thought to be
early in AD progression because of its link with plaques and NFT.
Oxidative stress by Aβ has been shown to be mediated by metal ions
[7, 9, 19]
Chronic Inﬂammation hypothesis During AD, cytokines, reactive oxygen species, complement proteins,
and prostaglandins are produced to cause chronic inﬂammation [11]
and forms plaques. Many studies have demonstrated that
Aβ plaques contain high levels of zinc and copper [23, 24].
The potential signiﬁcance of zinc in the aetiology of Aβ for-
mation and therefore AD is underscored by the fact that
the Aβ plaque load experienced by APP transgenic mice is
attenuated by crossing with mice that lack a zinc transporter
and are thus unable to transport zinc into synaptic vesicles
[25]. In the same vein, it is also worth noting that Aβ plaques
are concentrated in the most zinc-rich area of the brain, the
hippocampus [26],and levelsof hippocampal zinc have been
shown to be higher in AD brains than age-matched controls
[27]. A comprehensive review of AD and metal dyshomeo-
stasis is provided by Barnham and Bush [28].
Much of the insight we have gained with regards Aβ and
tau pathology has been obtained from speciﬁc genetic mu-
tations that account for a subset of AD (approximately 1%
of the disease as a whole) which is inherited in an autoso-
mal dominant manner [29]. There are three genes that have
been identiﬁed that cause familial AD (FAD). The ﬁrst FAD
mutationwasfoundintheAPPgenelocatedonchromosome
21 [30]. So far, twenty diﬀerent mutations aﬀecting the APP
gene causing FAD have been deﬁned [31]. The two other lo-
cations of FAD mutations are presenilin 1 (PS1) on chromo-
some 14 [32, 33] and presenilin 2 (PS2) on chromosome 1
[34, 35].
Although much progress has been made in our under-
standing of AD, this has not as yet been translated into either
eﬀective treatments or, crucially, an earlier or more accurate
diagnosis.
Currently, a ﬁrm diagnosis of AD requires histological
analysis of central nervous system (CNS) tissue to ﬁnd the
pathological changes described above and is thus a postmor-
tem one. Making a clinical, premortem diagnosis relies on
assessment of cognitive impairment and memory loss and
has been reported to be inaccurate in 10–15% of cases [36],
presumably due in part to the similarity of symptoms to
other diseases such as depression and other forms of demen-
tia. In addition, a clinical diagnosis is less than ideal because,
ﬁrstly, it is diﬃcult in the early stages to distinguish AD
fromnormalageingeﬀectsand,secondly,theabilitytodetect
cognitive impairment implies a signiﬁcant amount of dam-
age has occurred already, making possible treatments less
likely to be eﬀective.
These problems have led to signiﬁcant eﬀorts in identify-
ing biomarkers that could be used to diagnose and monitor
AD. There has been some promise in using magnetic reso-
nance imaging (MRI) to determine diﬀerential patterns of
brain atrophy [37] as well as using positron emission tomog-
raphy (PET) scanning to detect labelled Aβ plaques [36].
Other studies have shown that AD patients have higher levels
of tau protein and lower levels of Aβ42 in their cerebrospinal
ﬂuid (CSF) [38–41]. As worthy as these eﬀorts are, they are
not yet accurate enough to be useful for diagnosis with, for
example, the use of MRI to detect atrophy only able to dif-
ferentiate from normal subjects in 85% of cases [37, 42, 43],
which is not an improvement on clinical diagnosis. There is
also the not inconsiderable cost of these techniques to con-
sider, especially in the context of the prevalent nature of
AD, as well as the diﬃculties of compliance in this group of
patients.
A particularly promising strategy is the eye. Although re-
luctant to quote a clich´ e that has been adapted by the scien-
tific community from an even more hackneyed phrase, it is
true that the eye can be considered a window to the brain.
The retina exists as an extension of the CNS, and, thanks
to its purpose of receiving light and translating into vision,
it is optically transparent. Changes that occur in the retina
canbevisualisednoninvasivelyanddirectlywithincreasingly
sophisticated imaging techniques. As impressive as noninva-
sivelydetectinglabelledAβplaqueswithPETimagingis[36],
it is a far cry from the ability to detect changes in single neu-
rons as is now possible in the eye [44–47].International Journal of Alzheimer’s Disease 3
Table 2: Abnormalities detected in the visual pathway of AD patients.
Visual changes Manifestations References
Visual acuity Visual acuity changes reported in AD patients [50, 51]
Contrast sensitivity Several studies have reported changes in contrast
sensitivity in Alzheimer’s patients compared to controls [48, 52, 53]
Colour vision
Although controversial, many studies have demonstrated
colour vision deﬁciencies in AD patients, others reporting
prevalence to be high
[54–56]
Visual ﬁeld There are reports to suggest that AD patients exhibit visual
ﬁeld defects [57, 58]
Pupillary function AD patients have exhibited atypical pupil response to
cholinergic agonists and antagonists [59, 60]
Lens AD patients appear to be predisposed to a particular type
of cataract (equatorial supranuclear) [61]
Retina
AD patients have been shown to have a speciﬁc pattern of
RNFL thinning, perhaps related to the severity of AD. Also
shown to have decreased retinal blood ﬂow
Changes in retinal function using electrophysiological
t e s t s( P E R G sa n dV E P s )h a v eb e e ns h o w n
Aβ plaques have been demonstrated in the retinas of AD
patients
[62–70]
Historically, the visual symptoms that have long been re-
portedinADpatients(seelater)havebeenattributedtoneu-
ronal damage to the visual pathways in the brain rather than
the retina [48, 49]; however, there is increasing evidence that
the speciﬁc pathological ﬁndings in the brain occur in the
retina also, both in AD patients and transgenic AD animal
models.
2. Ocular Manifestation in
Alzheimer’s Patients (Table2)
2.1. Visual Deﬁcits in AD. Various diﬀerent aspects of vision
have been reported to be aﬀected in AD since Cogan’s ﬁnd-
ings in 1985 [71]. These include abnormalities in visual acui-
ty, [50, 51], contrast sensitivity [52, 72], colour vision [54,
55], and motion perception [73, 74].
2.2. Retinal Abnormalities. As would be expected, the major-
ity of the changes that have been observed in AD eyes are in
the retina.
Cross-sectionalimagingoftheretinausingopticalcoher-
ence tomography (OCT) has demonstrated in various stud-
ies that AD is associated with thinning of the peripapillary
retinal nerve ﬁbre layer (RNFL) [62–64] with the loss oc-
curring superiorly initially [65]. These in vivo ﬁndings cor-
respond with the predominantly inferior visual ﬁeld loss
experienced by AD patients [57]a n da r ec o r r o b o r a t e db y
histopathological ﬁndings of reduced number of RGCs and
axonal degeneration in postmortem AD retinas [75–77]. In
vivo imaging has also suggested a correlation of AD severity
and reduced thickness of the RNFL (presumably due to loss
of RGCs and axonal degeneration) at the macula [63]a sw e l l
as a decrease in RNFL thickness and neuroretinal rim of the
optic nerve head [78].
In vivo Doppler imaging techniques have demonstrated
a decrease in retinal blood ﬂow [65]a n a l o g o u st oc e r e b r a l
blood abnormalities demonstrated in AD [79], although
whether this is a primary phenomenon or simply a conse-
quence of a thinned retina is hard to say.
Another noninvasive technique which evaluates retinal
function is electrophysiology. Changes in pattern electroret-
inograms (PERG) and visual evoked potentials (VEPs) have
been noted in AD patients [66–68]w i t hs p e c i ﬁ cc h a n g e s
being correlated with RNFL thickness [69].
APP and Aβ immunoreactivity has been detected in an
age-dependent manner [80] in the retinas of AD patients,
and, even more excitingly (in terms of ﬁnding a retinal bio-
marker for AD), Aβ plaques have been demonstrated as a
postmortem ﬁnding in the retinas of AD patients [70]. A
comprehen-sivereviewhasbeen publishedonthis topic else-
where [81].
2.3. Other Ocular Abnormalities. AD patients have been
noted to suﬀer from a particular type of cataract, namely,
equatorial supranuclear, with Aβ deposition localised to the
opacities [61]. Similar cataracts have been noted in Down’s
syndrome subjects, further supporting deposition of Aβ in
thelensasthecause[82].Thisraisestheintriguingpossibility
t h a to n ec o u l dd e t e c tA β in the lens as a screening tool for
AD although clearly this would require the changes in the
lensprecedingthesymptomsofADwhichhasnotasyetbeen
proven. Itwould be interesting indeed if an ocularbiomarker
was found for AD that is not connected to the CNS.
A summary of these visual pathway signs and symptoms
that have been described in AD patients is presented in
Table 2.
Theseﬁndingsmakeacompellingcasetoinvestigateocu-
lar manifestations of AD further, and, for the remainder of4 International Journal of Alzheimer’s Disease
this paper, we shall look at what has been discovered using
animal models of AD.
3. AnimalModels of Alzheimer’s Disease
FAD accounts for less than 1% of AD cases [83, 84] and has
been shown to be due to the three genes mentioned above
(APP, PS1, and PS2) inherited in an autosomal dominant
manner.TheirrelativelysmallcontributiontotheADburden
as a whole is inversely proportional to the amount of infor-
mationwehavegleanedfromthem,bothintermsofforming
and conﬁrming hypotheses about the pathogenesis, and pro-
viding animal models.
The use of animal models in investigating any disease
process is important as they provide a way of standardising
the disease among subjects and can be experimented on in
ways that are simply not possible in human subjects.
Most of the animal models of AD are mice as, ﬁrstly, they
are mammals and therefore have a similar CNS structure to
humans, and, secondly, it is relatively easy and inexpensive
to produce transgenic strains expressing one or more of the
elucidated genes.
Currently,transgenicmicecomeinthreevarieties: single,
double, or triple transgenic simply referring to the number
of genes they express. The earliest mice models were single
transgenic which increased Aβ by increasing APP via a mu-
tant APP gene. Early examples include the PDAPP mice
which express an FAD mutation containing a valine residue
substitution at position 717 using a platelet-derived growth
factor-β promoter [85] and the Tg2576 mice which express
ad i ﬀerent FAD mutation characterised from a Swedish
family of FAD suﬀerers (K670N/M671L) using a hamster
prion promoter [86]. Both these lines expressing diﬀerent
FAD-associated mutations and various others that have been
designed since [87–89] have shown amyloid deposition and
glial activation that increases with age [86, 90]a n do v e r a l l
have been successful in mimicking these neuropathological
a s p e c t so fA Da sw e l la sc o g n i t i v ed e ﬁ c i t s[ 88].
Althoughthesediﬀerent models do show signiﬁcant sim-
ilarities across diﬀerent studies, there are diﬀerences such as
timing ofonset ofthe amyloid plaques[91] which is presum-
ablyexplainedbythediﬀerenthoststrains,diﬀerentpromot-
ers, and diﬀerent speciﬁc mutations of each model.
APP mutations account for only a small proportion of
FAD [31], and mice expressing FAD mutations of PS1 and
PS2 have also been created. Transgenic mice containing
either FAD PS1 or PS2 mutations show elevated levels of
the relatively amyloidogenic Aβ42; however, these lines do
n o tg oo nt od e v e l o pp l a q u e s[ 92, 93], a ﬁnding that can be
explained by the fact that mice and rats lack two histidines
thatmakeuptheAβ metalbindingsite[20, 94, 95]andhigh-
light further the potential importance of zinc dyshomeosta-
sis mentioned earlier.
An a t u r a lf o l l o wo nf r o mt h i si st oc r e a t ed o u b l et r a n s -
genic mice containing both APP and PS1 or PS2 mutations.
Various combinations have been created and investigated,
and, in general, the addition of a PS1 or PS2 mutant gene
to the APP mutant gene accelerates the rate of amyloid depo-
sition and plaque formation [96–99].
A triple transgenic mouse model was created in 2003
containing APP, PS1, as well as tau transgenes [100]w h i c h
successfully recapitulated the amyloidogenic as well as the
NFT features of AD with the mice developing amyloid pla-
ques as well as NFTs.
More recently, rat models using the same principles have
been established that show similar rates of amyloid deposi-
tion [101–103] and have the theoretical advantage that be-
havioural studies will be more achievable than in mice.
Other avenues explored in rodent models are over ex-
pressing endogenous APP, knockout mice, mutations in
beta, gamma, and alpha secretase, ApoE, however, it is
beyond the remit of this paper to describe all these in
detail and the reader is directed toward a database of AD
animal models kept by the Alzheimer research forum at
http://www.alz-forum.org/res/com/tra and two comprehen-
sive reviews on AD animal models from Spires and Hyman
and from Duyckaerts et al. [31, 104].
Worth brieﬂy mentioning are nonrodent models of AD
which, while having the obvious disadvantage of being so
phylogenetically distinct from humans, have the advantages
that they are easier, cheaper, and quicker to perform exper-
iments on. The Drosophila fruit ﬂy contains a homolog of
APP [105] and presenilin [106] as does the nematode ceano-
rhabditis elegans [107, 108]. Overexpression of these endog-
enous proteins as well as transgenic expression of human
mutant APP, PS, and tau genes in these species has certainly
contributed to this ﬁeld however not to the same extent as
their rodent counterparts.
The remainder of this paper will focus on what we have
learnt speciﬁcally from the eyes of these animal models.
4. Ocular Manifestations of Alzheimer’s
DiseaseinAnimalDisease Models
4.1. Retinal Changes (Table 3)
4.1.1. Amyloid β Deposition. Several studies using transgenic
AD mouse models have demonstrated the presence of Aβ
in the retina. One study by Liu and colleagues [109] used
the previously described single transgenic Tg2576 mouse
modelwhichcontainstheAPPdoubleSwedishmutationand
shows an age-dependent deposition of extracellular Aβ and
amyloidplaquesinthecerebellum,hippocampus,andcortex
as well as displaying cognitive deﬁcits [86]. In this study, they
demonstrated extracellular Aβ immunoreactivity and plaque
like formation using four diﬀerent monoclonal antibodies
as well as Congo red staining in Tg2576 retinas. The Aβ
deposition occurred predominantly from the ganglion cell
layertotheouternuclearlevelwithplaquesevenfoundinthe
photoreceptorlayerandopticnervehead.Anotherstudythat
utilisedthe Tg2576 mousemodel waslesssuccessfulhowever
in detecting Aβ deposition [111]. Here, Aβ immunoreac-
tivity was tested using the Aβ monoclonal mouse antibody
1E8 and was only found in the retinal periphery with no
plaque like structures detected. Of relevance is the fact that,International Journal of Alzheimer’s Disease 5
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in the same study, plaque-like structures were found in the
cerebral cortex of the same animals using the same antibody.
Also interesting to note is that the diﬀerences in the studies
cannot be explained by a disparity in age of the animals as
Liu et al. mice were aged 14 months as were the animals used
byDutescuetal.suggesting,perhaps,adiﬀerentialsensitivity
of the Aβ antibodies used.
Retinal Aβ deposition has also been found in double
and triple transgenic mouse models expressing APP and PS
mutations. One study used two diﬀerent strains of APP/PS
mice [112]. In the ﬁrst strain which contained mutant
human APP and PS1 genes (Tg2576 × Tg1), they found that
extracellular Aβ deposition, as determined by immunoreact-
ivity to a monoclonal mouse Aβ antibody, was present
predominantly in the nerve ﬁbre layer and ganglion cell layer
in animals aged 27 months but not at the younger age of 7.8
months. In the second strain containing the same APP mu-
tant gene but with a diﬀerent PS1 gene (APPswe/PS1ΔE9),
there was a similar pattern of Aβ immunoreactivity predom-
inantly in the nerve ﬁbre and ganglion cell layer although
these animals were at an intermediate age of 10.5 months.
This second strain (APPswe/PS1ΔE9) has been used in two
subsequent studies facilitating a comparison of sorts. In
one of these studies by Perez and colleagues [113], Aβ
plaques, as determined by thioﬂavin-S and conﬁrmed with
immunostaining, were found from 12 months old but
predominantly in the inner and outer plexiform layers with
far fewer plaques present in the GCL, INL, and ONL. This
ﬁtsinwiththetemporalﬁndingsofNingetal.’sstudybutnot
withthelocalisation.Anotherstudyutilisingthesamemouse
m o d e li sf r o mD u t e s c ua n dc o l l e a g u e s[ 111]. In this study,
moderate Aβ deposition was detected in the GCL, IPL, INL
and OPL in 9-month-old mice. Overall these results seem
rather inconclusive; however, the lack of Aβ plaques found
in Ning and Dutescu’s work is potentially explained by the
fact that they were looking at an earlier time point than the
earliest point at which plaques were detected (12 months) in
Perez’ study.
One study has further characterised that the relatively
amyloidogenic form of Aβ,A β42, is deposited in the GCL,
INL, and ONL of APP single transgenic and APP/PS1 double
transgenic mice [114].
Recent studies using a triple transgenic mouse model
expressing APP, PS1, and tau mutations have also demon-
stratedincreasedAβ depositionacrosstheretina,particularly
in the GCL and the inner segments of photoreceptor [47,
115].
A particularly exciting ﬁnding is that, in double trans-
genic mice (APPswe/PS1ΔE9), retinal Aβ plaques can be
stained with curcumin and imaged safely in vivo [70]. In the
same study, they demonstrated that the retinal plaques de-
tected ex vivo occurred prior to plaques in the brain. This is
hugely relevant as it suggests that retinal changes could po-
tentially be used to make a diagnosis of AD, noninvasively,
prior to even the current gold standard of postmortem histo-
logical analysis.
Aβ has also been detected in the retinal and choroidal
vasculature of animal models in keeping with the corollary
in the brain; cerebral amyloid angiopathy [110, 116, 117]. In
27-month-old double transgenic mice (Tg2576 × Tg1), Aβ
immunoreactivity was detected in both retinal and choroidal
microvasculature which was not present in younger (7.8
months) animals. At an intermediate age (10.5 months) Aβ
immunoreactivity was present in the choroidal vasculature
only [112]. It should be noted that the intermediate aged
animals, although double transgenic for APP and PS1 as
with the 7.8- and 27-month old animals, contained diﬀerent
mutations. Another study using Tg2576 single transgenic
mice [109]d e t e c t e dA β deposition in retinal capillaries of
14-month-old mice. Interestingly, administration of amy-
loid peptide vaccinations increased this vascular deposition
despite decreasing the extracellular plaques which mirrors
what occurs in brains of mice models [118]a n ds u p p o r t s
the theory that immunotherapy solubilises Aβ allowing it to
drain via the vascular system [119].
4.1.2. APP Immunoreactivity. As one would expected APP
has been detected in the retina of the same animals that
exhibit Aβ deposition.
In single transgenic Tg2576 mice which overexpress APP,
Liu et al. [109]d e t e c t e di m m u n o r e a c t i o no fA P Pi nt h eG C L
and INL of 14-month-old animals. This was corroborated in
a separate study using the same animals of a similar age
[111].
In double transgenic mice (Tg2576 × Tg1), APP was
likewise detected in the GCL and INL of 27-month-old
animals although was not present in younger, 7.8-month-
old, mice. Unlike the Tg2576 single transgenic mice, APP
wasdetectedtoasmalldegreeintheRPEandphotoreceptors
[112]. In the same study, a diﬀerent double transgenic strain
(APPswe/PS1ΔE9) exhibited APP immunoreactivity only in
the GCL at an intermediate age of 10.5 months. The same
animal model in a diﬀerent study [111] showed moderate
APP staining in the IPL and OPL in 9-month-old animals.
APP immunoreactivity has also been detected in the
retina of a double transgenic mouse model containing the
Swedish APP mutation and a PS1 knock in, although this
study did not clarify in which layers this was conﬁned to
[114].
4.1.3. Tau Protein. The hyperphosphorylation of the micro-
tubule-associated protein tau and subsequent deposition as
neuroﬁlbrillary tangles is associated with various neurode-
generative disorders (collectively called tauopathies) such
as progressive supranuclear palsy, frontotemporal dementia,
and parkinsonism linked to chromosome 17 and AD [120,
121]. Tau inclusions have been observed in the brains of AD
transgenic mice [100, 122, 123] and appear to be a feature
of the AD retina as well. In single transgenic Tg2576 mice
overexpressing APP, hyperphosphorylated tau was detected
using the AT8 antibody adjacent to the Aβ deposition from
theGCLthroughtotheONL[109].Adiﬀerentmousemodel
that expresses the human P301S tau transgene and develops
tauinclusionsthroughoutthecentralnervoussystem[124]is
used as a model for tauopathies rather than speciﬁcally AD.
In this transgenic line, hyperphosphorylated tau was foundInternational Journal of Alzheimer’s Disease 7
in the RNFL which progressed to tau inclusions in the GCL
with associated deleterious eﬀects on axonal growth [120].
4.1.4. Neuroinﬂammation. Activated microglia and astro-
cytes are thought to initiate neuroinﬂammation in AD and
have been shown to be upregulated in the brains of mouse
models of AD [125, 126]. Microglial activation in the retina
has been shown in mouse models of retinal degeneration
[127].Itisthenrelativelyunsurprisingthatsigniﬁcantupreg-
ulation of inﬂammation has been detected in the retinas of
AD mouse models.
In Tg2576 single transgenic mice, there was increased
activation of astrocytes and microglia in all layers of the
retina compared to wild-type controls as detected using cell-
speciﬁc markers GFAP for astrocytes and IBA1 for microglia
[109]. Immunisation with amyloid peptide vaccinations in
the same study led to increased neuroinﬂammation in the
retinainaccordancewithsimilarﬁndingsinthebrainsofAD
mouse models [128].
In double transgenic mice (APPswe/PS1ΔE9), microglial
activation was signiﬁcantly higher than in age-matched con-
t r o l sa sd e t e c t e du s i n gam a c r o p h a g em a r k e rF 4 / 8 0[ 113].
The same study used GFAP to look for astrocytic activation
and found that there was no measurable upregulation.
In the same double transgenic model aged 10.5 months,
another study found that monocyte chemotactic protein
(MCP) 1, a relatively nonspeciﬁc marker of inﬂammation
was increased in the GCL (the same area as Aβ deposition
was occurring) compared with wild-type controls although
F4/80immunoreactivitywasnotsigniﬁcantlydiﬀerent[112].
Ad i ﬀerent double transgenic model (Tg2576 × Tg1) in the
same study found that, at a younger age, F4/80 and MCP-
1 immunoreactivity was signiﬁcantly less than at a higher
age of 27 months leading them to conclude that this was
due to progression of AD and that the MCP-1 but not F4/80
immunoreactivity in the intermediate aged mice represented
a relatively early stage of inﬂammation prior to microglial
activation. While this may well be true, the lack of a wild-
type control at the young and old ages makes it hard to be
sure that this is not merely an ageing eﬀect independent of
AD.
Another ﬁnding that suggests an important role of neu-
roinﬂammation in the propagation of AD and indeed other
neurodegenerative disorders is a consistent downregulation
of complement factor H (CFH) in AD brain [129]. CFH is
a cofactor that acts to suppress the alternative complement
pathway; hence, low levels of CFH have a proinﬂammatory
eﬀect. One paper evaluated the presence of CFH and Aβ40
and Aβ42 peptides in the brains and retinas of several
diﬀerent transgenic AD mouse models (Tg2576, PSAPP, 3
× Tg-AD, and 5 × FAD) and found that there was a con-
sistent inverse correlation between levels of Aβ and CFH
in the retinas of these transgenics [130] suggesting that an
environment promoting complement activation is a feature
of AD retinas. Interestingly, CFH has also been implicated
in the pathogenesis of AMD [131], another neurodegener-
ative disease aﬀecting the retina suggesting, perhaps, a
similar contribution of neuroinﬂammation to these diseases.
Research into AMD has suggested a link between CFH and
zinc. Zinc has been shown to cause aggregation of CFH
monomers [132] which, combined with the high levels of
CFH and zinc [133] that are found in the sub-RPE deposits
(drusen) that characterise this disease, suggest a critical role
for zinc analogous to the one it is postulated to play in AD.
Unfortunately, to the best of our knowledge, there is no
research that has looked at levels of zinc in the retina of AD
animal models.
4.1.5. Neuronal Cell Loss. In common with other neurode-
generative diseases, cell death and loss of neurons is an end
stage of AD.
In double transgenic mice (Tg2576 × Tg1), a signiﬁcant
increase in apoptosing cells in the GCL of 27-month-old
animals compared with 7.8 month old animals was detected
using terminal deoxynucleotidyl transferase mediated dUTP
nick end labeling assay (TUNEL) [112] .T h es a m es t u d ya l s o
found an increase in TUNEL-positive cells in the GCL of
ad i ﬀerent double transgenic model (APPswe/PS1ΔE9)c o m -
pared with age-matched controls.
In single transgenic Tg2576 mice, using retinal thickness
as a measure of neuronal loss, a reduced thickness was
detected compared with wild-type controls [109]. In addi-
tion, administration of amyloid peptide vaccinations atten-
uated the reduction of retinal thickness in conjunction with
a reduction of Aβ deposition in these animals.
Using TUNEL to look at NMDA-induced apoptosis in
APP and PS1 single transgenic mice and APP/PS1 double
transgenic mice has yielded potential insight into how Aβ
may cause retinal degeneration [114]. In this study, APP and
APP/PS1 transgenic mice displayed fewer TUNEL-positive
cells in the GCL following injection of NMDA than wild-
type controls suggesting that deposition of Aβ may prevent
activation of NMDA-receptor pathways and mediate retinal
dysfunction in AD in this way. In the same study, however,
there was no detected diﬀerence in RGC number or INL
thickness (obviously a relatively crude measure of neuronal
loss) between the APP overexpressing single transgenic mice,
APP/PS1 double transgenic, and PS1 knockin mice and their
wild-type controls. This is clearly at odds with other studies
and may represent a diﬀerence in the strains used as well as
less sensitive methods of counting cells.
A relatively recent development now allows direct visu-
alisation of apoptosing ganglion cells in the retina. Using
a ﬂuorophore labelled annexin V protein as a marker of
apoptosis and confocal laser scanning ophthalmoscopy to
detect the ﬂuorescence, it is possible to image single apop-
tosing ganglion cells in real time and in vivo [44, 46]. This
technique has been reﬁned and used to visualise apoptosing
(labelled with annexin V) and necrosing (labelled with
propidium iodide (PI)) cells in a triple transgenic mouse
model of AD [47]. In this study, the triple transgenic
mice displayed increased RGC apoptosis and decreased RGC
necrosis compared with wild-type controls.
4.2. Other Ocular Changes. For obvious and very sensible
reasons, the retina has been the target of most of the research8 International Journal of Alzheimer’s Disease
looking at AD in the eye. It has though been established
that the lenses of AD patients, as mentioned earlier, contain
Aβ aggregates that colocalise with a speciﬁc type (equatorial
supranuclear) of cataract [61]. This appears to be similarly
manifested in AD mouse models with the epithelial cells of
the corneas and lenses of single transgenic Tg2576 mice and
double transgenic APP/PS1 mice, being immunopositive for
APP and Aβ [111].
5. Conclusion
The idea of using the retina as a means of diagnosing or
measuring progression of AD or any other neurodegener-
ative disease is an inherently attractive one for the reasons
outlined above, and the studies discussed here provide much
to be optimistic about. Perhaps one of the main advantages
of using the retina is the ability to noninvasively look directly
at the nervous system. Much of the evidence discussed above
shows that changes in the retina occur later than in the
brain. The single transgenic Tg2576 mouse model has been
shown to develop Aβ plaques in the brain at 9 months
[86], while similar changes occur in the retina at 14 months
[109, 111]. There is a similar pattern when looking at double
transgenic mouse models with the Tg2576 × Tg1 model
showing increased levels of Aβ40 and Aβ42 in the brain by
3-4 months [99] while not being raised in the retina of 7.8-
month-old animals [112].
However, a recent study looking at double transgenic
mice has shown very clearly that Aβ plaques appear earlier
in the retina than in the brain by examining the same
animals over time [70] and, further, that they can be imaged
noninvasivelyatthisearlystage.Thisﬁndingraisestheproﬁle
of the retina as a potential source of an earlier diagnosis
in AD although it remains to be seen whether this ﬁnding
is replicated in other studies and in human subjects. As
discussed earlier, the role of zinc in the formation of Aβ
plaquesappearstobesigniﬁcantandthefactthattheretinais
a particularly zinc-rich tissue [134]bod e sw ellf o ra n yp l a q u e
pathology being detectable relatively early in the disease.
The rationale for investigating the retina is that, as an
extensionoftheCNS,itisreasonabletoexpecttoﬁndsimilar
changes as occur in the brain. A side eﬀect of this research,
however, has been the ﬁnding that Aβ deposition occurs
in the lenses of AD subjects [61] and has been found in
lenses and corneas of single and double transgenic animal
models [111]. Aβ deposition and hyperphosphorylated tau
have also been detected in the lenses and corneas of triple
transgenic mice [81] raising the slightly unexpected but
equally welcome possibility that an ocular biomarker for AD
may exist that is not connected with the CNS.
Although great progress has been made in this area, there
remain signiﬁcant questions. Firstly, Aβ plaques have only
beendetectedinhumanADsubjectsinonestudy[70],andit
is this same study that provides the only evidence that retinal
pathology precedes brain pathology; both ﬁndings that need
to be corroborated. Secondly, there appears to be signiﬁcant
crossover of AD with other causes of neurodegeneration.
Glaucoma, for example, is a neurodegenerative disease that
results in loss of RGCs and manifests with RNFL thinning
and visual ﬁeld defects (i.e,. similar ﬁndings as those
describedforADpatients),thathavebeenreportedashaving
a higher incidence in AD [56]. It is possible that the changes
thus far reported in the eyes of AD patients and animal
models are not as speciﬁc for AD as we might hope.
Thirdly, putting aside the question as to whether changes
in the eye precede those of the brain, it is suggested that
cognitive deﬁcits of AD may come before detectable amyloid
pathology in the brain [99] meaning that a holy grail
of detecting AD before its symptoms manifest (implying
signiﬁcantlossofneurons)bydetectingamyloidplaquesmay
not be possible.
Nevertheless, as an absolute minimum, the ability to
image the retina (and rest of the eye) noninvasively and
relatively cheaply and quickly cannot but massively aid in
assessing possible treatment eﬀects of anti-AD, therapies as
well as improve our knowledge of the underlying mecha-
nisms of this and other forms of neurodegeneration. In com-
mon with AD there is much evidence linking zinc dysho-
meostasis with the onset of AMD, the leading cause of
blindness in the developed world, with large amounts of
zinc found in drusen [133]. An apparent contradiction is
that zinc supplements (presumably in their antioxidant role)
have been shown to be beneﬁcial in the nonneovascular
type of AMD (so called dry AMD) [135]. This is putatively
explained in a review by Nan et al. [136] by the fact that, as
mentioned above, zinc causes aggregation of CFH. The high
concentration of zinc found in drusen leads to a localised
aggregation of CFH causing the sustained inﬂammatory
response necessary for initiation of the disease. Later in
the disease, the tissue surrounding the zinc-rich drusen is
relatively zinc depleted and hence supplementation is bene-
ﬁcial. This is a typical example of the commonalities be-
tween diﬀerent neurodegenerative diseases and highlights
how research into one area is likely to beneﬁt in others.
Overall, the research looking at manifestations of AD in
the eyes of animal models is notable by its paucity and it is
diﬃcult at this early stage to draw any ﬁrm conclusions other
than that this is an extremely promising area of investigation
and certainly warrants further research.
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